CCA
OREX

Catalyst Capital Advisors’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Catalyst Capital Advisors’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-25,000
Closed -$1.06M – 620
2014
Q3 		$1.06M Buy
+25,000
New +$1.34M 0.14% 155

Other funds holding OREX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Catalyst Capital Advisors's OREX Position: Q4 2014 in Review

Catalyst Capital Advisors sold out of Orexigen Therapeutics, Inc. (OREX) in Q4 2014, closing a stake of 25,000 shares — an estimated $1.06M sold.

Catalyst Capital Advisors first reported a position in OREX in Q3 2014 and held it in 1 quarter. The position peaked at $1.06M in Q3 2014. 147 funds tracked by Wall St. Rank hold OREX as of Q4 2014.

  • Catalyst Capital Advisors reported no remaining Orexigen Therapeutics, Inc. position as of Q4 2014 after selling out during the quarter.
  • Catalyst Capital Advisors sold 25,000 Orexigen Therapeutics, Inc. shares in Q4 2014, an estimated $1.06M.
  • Catalyst Capital Advisors first reported a position in Orexigen Therapeutics, Inc. in Q3 2014 and held it in 1 quarter.
  • Catalyst Capital Advisors's Orexigen Therapeutics, Inc. position peaked at $1.06M in Q3 2014.
  • 147 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2014.

Based on Catalyst Capital Advisors's 13F filing for Q4 2014, filed 10 Feb 2015.